parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.09 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in adrenal medulla cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 166	0.79
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3005

receipt 3014: UNC5C in dopamine neurons, braak

power: full sample -0.23 (p 0.365, n 18), 95% CI -0.63 to +0.27. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.365, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.30 (p 0.225, n 18). could be the mix.
skeptic: leave-one-out range -0.35 to -0.12, sign flips 0; without severely affected donors -0.23 (p 0.365, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for UNC5C in dopamine neurons.

case closed: nothing better to follow up.

receipt 3013: UNC5C in oligodendrocytes, braak

power: full sample +0.20 (p 0.418, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.25 (p 0.315, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.22 (p 0.379, n 18). could be the mix.
skeptic: leave-one-out range +0.10 to +0.36, sign flips 0; without severely affected donors +0.20 (p 0.418, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for UNC5C in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts